Originally published by our sister publication Infectious Disease Special Edition
By Fran Kritz
This story was updated May 15, 2025 at 4:48 p.m. after the CDC director acccepted the ACIP recommendation on Chikungunya vaccine.
The FDA and CDC recently issued a joint advisory statement recommending a pause in the use of the chikungunya vaccine, live (Ixchiq, Valneva SE), in people 60 years of age and older, while they investigate reports of serious adverse events (AEs).
Ixchiq, approved by the